Oncology Central

Lenvatinib vs sorafenib in unresectable HCC: an interview with Arndt Vogel

0

We recently caught up with Arndt Vogel from Hanover Medical University (Germany) to learn about clinically meaningful data from a pivotal Phase III study which indicates that lenvatinib is non-inferior to sorafenib in median overall survival for the first line systemic treatment of patients with unresectable hepatocellular carcinoma (HCC). In this interview you can find out about the current treatment options for unresectable HCC, the design and results of the REFLECT trial and the clinical significance of its findings.

What are the current treatment options for unresectable HCC?

  • The rate of liver cancer has been rising steadily over the past decade and mortality rates remain high. More than 70% of patients who have advanced disease at the time of diagnosis are not candidates for curative treatment modalities such as surgery. Patients with intermediate disease can, in most cases, be initially treated with local therapies such as transcatheter arterial chemoembolization (TACE). Patients not responding to TACE or with extra hepatic disease require systemic therapy.
Share:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.